ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $14.00.

Several analysts have recently weighed in on ALXO shares. Stifel Nicolaus reiterated a “hold” rating and issued a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Monday, August 12th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. UBS Group reduced their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Finally, Lifesci Capital downgraded ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st.

ALX Oncology Stock Performance

ALXO stock opened at $2.22 on Friday. The firm has a market cap of $116.93 million, a PE ratio of -0.60 and a beta of 1.01. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average price of $3.91 and a 200-day moving average price of $9.24. ALX Oncology has a 1-year low of $1.88 and a 1-year high of $17.83.

ALX Oncology (NASDAQ:ALXO) last issued its earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01. As a group, equities research analysts expect that ALX Oncology will post -3.04 earnings per share for the current year.

Insider Transactions at ALX Oncology

In other news, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $7.90, for a total value of $158,000.00. Following the completion of the sale, the insider now directly owns 593,447 shares of the company’s stock, valued at $4,688,231.30. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 28,398 shares of company stock valued at $200,043 over the last three months. Corporate insiders own 33.40% of the company’s stock.

Institutional Trading of ALX Oncology

Institutional investors have recently made changes to their positions in the company. Jump Financial LLC purchased a new position in shares of ALX Oncology in the 4th quarter worth approximately $371,000. Dynamic Technology Lab Private Ltd purchased a new position in ALX Oncology in the fourth quarter worth $215,000. TD Asset Management Inc bought a new position in ALX Oncology in the 4th quarter valued at $1,048,000. Vestal Point Capital LP purchased a new stake in shares of ALX Oncology during the 4th quarter valued at $24,643,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of ALX Oncology by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock worth $107,000 after purchasing an additional 3,825 shares during the period. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.